

## 1 **Supplemental A**

### 2 **Phenotypic classification (Adapted from Arends et al (2016) with permission)**

3  
4 Patients were classified as classical or non-classical FD on the basis of their enzyme activity  
5 (men only) and the presence or absence of characteristic symptoms (Smid et al 2014). Men  
6 were considered to have a classical phenotype when they met the following criteria: 1) a GLA  
7 mutation, 2) enzyme activity  $\leq 5\%$  of the mean reference range, 3)  $\geq 1$  characteristic FD  
8 symptoms (i.e. Fabry neuropathic pain, angiokeratoma and/or cornea verticillata, for  
9 definitions see (van der Tol et al 2014)). Men not fulfilling these criteria were categorized as  
10 non-classical FD.

11  
12 Women with a GLA mutation and  $\geq 1$  characteristic FD symptoms (i.e. Fabry neuropathic  
13 pain, angiokeratoma and/or cornea verticillata (van der Tol et al 2014)) were classified as  
14 having a classical phenotype. Women without these characteristic FD symptoms were  
15 classified as non-classical FD.

16  
17 Classification on the basis of phenotypic features and residual enzyme activity was  
18 challenging in two groups of patients. It was decided that in these cases a final judgement was  
19 made by the treating physician. These groups were:

20 1) Patients with the N215S mutation: this group is especially prevalent in the UK. According  
21 to literature and physician experience, patients exhibit a non-classical (mostly cardiac)  
22 phenotype, but exceptions may occur. In this group of 90 patients, 12 had a characteristic  
23 symptom, but without confirmatory deficiency of GLA activity in leucocytes in men ( $n = 5$ ).  
24 Notably, one of the N215S patients presented with severe renal disease at young age and had  
25 a renal transplantation at age 29. According to the judgement of the treating physician this  
26 patient was classified as classical FD while the other N215S patients were all classified as  
27 non-classical FD. Similarly, three patients with characteristic symptoms and the P389A  
28 mutation (1 man, 1 woman) or R112H (1 woman) mutation were discussed with the treating  
29 physician. These patients all had a late onset presentation, only minimal cornea verticillata (no  
30 other characteristic FD symptoms) and a family history of non-classical FD. Consequently  
31 they were classified as non-classical FD.

32  
33 2) Men with slightly higher than 5% enzyme activity in the presence of 1 or more  
34 characteristic symptoms ( $n = 13$ ). Residual enzyme activity ranged from 6% to 10% in  
35 leucocytes ( $n = 10$ ), and from 6% to 20% in plasma ( $n = 3$ ). All had at least one characteristic  
36 FD symptom and the majority had a relative with classical FD and consequently were  
37 considered having classical FD. In four men the enzyme activity and/or the data on  
38 characteristic FD symptoms were missing. These patients were classified as classical FD  
39 according to the opinion of the treating physician, which was mainly based on their family  
40 history.

41 Furthermore, we included three patients (one man, two women, all from the same family)  
42 with the A143T mutation. They were classified as having classical FD based on the

43 combination of characteristic deposits on renal biopsy or post mortem biopsy, the presence of  
 44 one or more characteristic FD symptoms, low enzyme activity (3.9%, 21% and 38%  
 45 respectively) and high plasma lysoGb3 concentrations (men: 35-50 nmol/l while receiving  
 46 ERT; woman 1: 16 nmol/l while receiving ERT; woman 2: 8 nmol/l while not receiving  
 47 ERT). In these cases, a combination of the A143T mutation and an unknown mutation and/or  
 48 other (genetic) disease modifiers may have caused the classical FD presentation.  
 49  
 50

---

**Supplemental table A**

Criteria for phenotypic classification

---

*Classical FD*

---

Men	Women
<ul style="list-style-type: none"> <li>▪ A mutation in the GLA gene*</li> <li>▪ <math>\geq 1</math> of the following characteristic Fabry disease symptoms: Fabry neuropathic pain, angiokeratoma and/or cornea verticillata</li> <li>▪ Severely decreased or absent leukocyte AGAL activity (&lt;5% of the normal mean)</li> </ul>	<ul style="list-style-type: none"> <li>▪ A mutation in the GLA gene</li> <li>▪ <math>\geq 1</math> of the following characteristic Fabry disease symptoms: Fabry neuropathic pain, angiokeratoma and/or cornea verticillata</li> </ul>

---

*Non-classical FD*

---

- A mutation in the GLA gene, and not fulfilling the criteria for classical FD

---

*\*The following genetic variants were not considered FD (neutral variants): A143T, P60L, D313Y, R118C, T385A, IVS0-10 C>T, the complex haplotype: IVS0-10 C>T/IVS4-16A>G/IVS6-22C>T. In patients in whom classification on the basis of these criteria was not feasible, the final judgement was made by the treating physician.*

---